Article info
PDFTherapeutics
Original Article
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
- Correspondence to Maarten Arends, Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam 1100 DD, The Netherlands; m.arends{at}amc.uva.nl
Citation
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
Publication history
- Received June 12, 2017
- Revised January 7, 2018
- Accepted January 12, 2018
- First published February 7, 2018.
Online issue publication
June 15, 2020
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/